Clinical Trial Update: Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial investigating gemcitabine and nab-paclitaxel with momelotinib in untreated metastatic pancreatic ductal adenocarcinoma was terminated; results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Momelotinib (momelotinib)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Sierra Oncology LLC - a GSK company | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: TERMINATED | Results posted: 2018-05-09